Literature DB >> 18214681

Characterisation of the Bax-nucleophosmin interaction: the importance of the Bax C-terminus.

Jane Thompson1, Keith Finlayson, Eliane Salvo-Chirnside, David MacDonald, James McCulloch, Lorraine Kerr, John Sharkey.   

Abstract

The molecular chaperone nucleophosmin has been identified as a novel Bax binding protein with this interaction proposed to be a key event in the activation and translocation of Bax in mitochondrial dysfunction and apoptotic cell death. Using a proximity assay, we have quantitatively defined the high affinity and saturable interaction between Bax and nucleophosmin indicative of a competitive and specific mechanism. Binding of full length Bax to nucleophosmin was only observed after conformational change was induced using non-ionic detergents (e.g., NP-40). The Bax-nucleophosmin interaction was inhibited by a Bax C-terminal antibody (IC(50) = 1 nM) but minimally affected by antibodies directed against either the N-terminus or alpha-helices 4 and 5. Bcl-2 and p53 inhibited the interaction between full length activated Bax and nucleophosmin. The proximity assay based on the Bax-nucleophosmin interaction was robust and reproducible (Z' = 0.50) facilitating its use for screening a small chemical library. A low molecular weight non-peptide compound, 2-(5-methyl-2-phenyl-1,3-thiazol-4-yl)ethanohydrazide, partially inhibited the Bax-nucleophosmin interaction (IC(50) = 100 nM) and also attenuated UV-induced cell death of HEK293 cells. The present investigations demonstrate the importance of exposure of the C-terminus of Bax for its interaction with nucleophosmin. These protein-protein interaction assays provide a technical approach both for the study of Bax-interacting proteins and for the discovery of novel anti-apoptotic agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18214681     DOI: 10.1007/s10495-007-0177-2

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  9 in total

1.  Nucleophosmin Phosphorylation as a Diagnostic and Therapeutic Target for Ischemic AKI.

Authors:  Zhiyong Wang; Erdjan Salih; Chinaemere Igwebuike; Ryan Mulhern; Ramon G Bonegio; Andrea Havasi; Steven C Borkan
Journal:  J Am Soc Nephrol       Date:  2019-01       Impact factor: 10.121

Review 2.  The nuclear envelope: target and mediator of the apoptotic process.

Authors:  Liora Lindenboim; Hila Zohar; Howard J Worman; Reuven Stein
Journal:  Cell Death Discov       Date:  2020-04-27

3.  Nucleolar NF-κB/RelA mediates apoptosis by causing cytoplasmic relocalization of nucleophosmin.

Authors:  N Khandelwal; J Simpson; G Taylor; S Rafique; A Whitehouse; J Hiscox; L A Stark
Journal:  Cell Death Differ       Date:  2011-06-10       Impact factor: 15.828

4.  Mechanisms of nucleophosmin (NPM)-mediated regulated cell death elucidated by Hsp70 during renal ischemia.

Authors:  Zhiyong Wang; Andrea Havasi; Aaron A Beeler; Steven C Borkan
Journal:  Apoptosis       Date:  2021-11-11       Impact factor: 4.677

Review 5.  The NF-κB Nucleolar Stress Response Pathway.

Authors:  Hazel C Thoms; Lesley A Stark
Journal:  Biomedicines       Date:  2021-08-25

6.  Nucleophosmin, a critical Bax cofactor in ischemia-induced cell death.

Authors:  Zhiyong Wang; Jonathan M Gall; Ramon Bonegio; Andrea Havasi; Katarina Illanes; John H Schwartz; Steven C Borkan
Journal:  Mol Cell Biol       Date:  2013-03-04       Impact factor: 4.272

Review 7.  Blocking peptides and molecular mimicry as treatment for kidney disease.

Authors:  Andrea Havasi; Weining Lu; Herbert T Cohen; Laurence Beck; Zhiyong Wang; Chinaemare Igwebuike; Steven C Borkan
Journal:  Am J Physiol Renal Physiol       Date:  2016-09-21

Review 8.  The nuclear envelope: target and mediator of the apoptotic process.

Authors:  Liora Lindenboim; Hila Zohar; Howard J Worman; Reuven Stein
Journal:  Cell Death Discov       Date:  2020-04-27

Review 9.  Crosstalk between NF-κB and Nucleoli in the Regulation of Cellular Homeostasis.

Authors:  Jingyu Chen; Lesley A Stark
Journal:  Cells       Date:  2018-10-05       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.